Abstract:Objective To investigate the inhibitory effect of soluble HLA-G1 (sHLA-G1) on the cytolytic function of NK-92, and the relation of sHLA-G1 receptors, ILT2 and KIR2DL4, to the inhibition. Methods ①Recombinant sHLA-G1 was obtained by prokaryotic expression and verified by Western blot. ②NK-92 cells were treated with the recombinant sHLA-G1 at 20 μg/ml for 10 or 30 min, and then added with, anti-HLA-G1/G5 mAb, anti-ILT2 Ab, and anti-KIR2DL4 mAb. NK-92 without treatment served as a positive control. The expression of sHLA-G1, ILT2, and KIR2DL4 on the surface of NK-92 cells was analyzed with flow cytometry. ③Human leukemia cells K562 was used as target cells and the NK-92cells treated with recombinants sHLA-G1 as the effecters. The effecters and target cells was co-cultured for 2 h at a ratio of 5:1. Then, flow cytometry was used to detect the death rate of K562 cells. Before the co-culture, the effecter, NK-92 cells were divided into two groups. In one group, the NK-92 was treated with 0, 10, or 20μg/ml recombinant sHLA-G1 for 30 min; and in the other group, it was first incubated with anti-ILT2 Ab, or anti-KIR2DL4 mAb, or both, for 30 min, and then co-cultured with 0, 10, or 20μg/ml recombinant sHLA-G1 for 30 min. Results ①The recombinant protein was verified as having a histidine tag by Western blot. ②Compared with the control, the positive rate of sHLA-G1 expression was significantly increased and that of the ILT2 and KIR2DL4 was significantly decreased in the NK-92 cells treated with 20 μg/ml recombinant sHLA-G1 for 30 min (P 0.05). ③After being co-cultured with 0, 10, or 20 μg/ml recombinant sHLA-G1-treated NK-92, the death rate of the K562 reached 39.79% ± 2.00%, 27.79% ± 0.75%, or 21.36% ± 0.67% (one-to-one compared, P 0.05). When the ILT2 was blocked, the death rate was 23.09% ± 1.63%, 21.13% ± 0.38%, and 18.42% ± 0.47% (one-to-one compared, P 0.05); and when the KIR2DL4 was blocked, it was 30.74% ± 0.44%, 26.03% ± 0.38%, 21.15% ± 0.35% (one-to-one compared, P 0.05). Conclusion sHLA-G1 can inhibit the cytolytic function of NK-92 by directly binding to ILT2 and KIR2DL4.

[In Vitro Refolding and Functional Study of Soluble HLA-G1-peptide Complex].

Refolding and identification of soluble HLA-G1-peptide complex in vitro

In vitro Refolding and Tetramerization of Soluble HLA-A*2402-pBRLF1 Complex

In-vitro refolding and biotinylation of soluble HLA-A2-peptide complex]

[Improvement of Refolding Efficiency of HLA-A2-peptide Complex in Vitro by Preformed Disulfide Bonds in Heavy Chain].

Preparation of the Soluble HLA-A*0201-Antigenic Peptide Complex

Expression,purification and Activity Indentification of HLA-G1

The prokaryotic sHLA-G1 refolded in vitro inhibits T cell proliferation in mixed lymphocytes culture

[Construction and Characterization of Soluble HLA-A*0201-PR1 Complex].

In vitro expression and purification of heavy chain and β_2m of soluble HLA-G1

[Immune Tolerance Inducing Effects of Soluble Human Leucocyte Antigen G1 on Natural Killer Cells and T Cells].

In Vitro Expression and Purification of Heavy Chain and Β2m of Soluble HLA-G1

Dimerization of soluble HLA-G by IgG-Fc fragment augments ILT2-mediated inhibition of T-cell alloresponse.

Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules.

Structural and Functional Characterization of Peptide–β2m Fused HLA-A2/MART127–35 Complexes

Recombinant Expression of the<i>β</i>-Subunit of HLA-DR10 for the Selection of Novel Lymphoma Targeting Molecules

Interactions Between Shla-G1 and Its Receptors ILT2, and KIR2DL4 on NK-92 Cells

The anti-leukemia effect of heat shock protein-peptide complex-96

A novel one-step strategy for the preparation of HLA/HBc 18–27 and HLA/CEA 694–702 complexes with ion exchange chromatography

[Expression and Refolding of a HLA-A*0203-BSP Fusion Protein and Identification of Its Tetramers].

Efficient in Vitro Refolding and Characterization of Major Histocompatibility Complex Class I-Related Chain Molecules A (MICA) and Natural Killer Group 2 Member D (NKG2D) Expressed in E. Coli